1. Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer.
- Author
-
Pedernera E, Gómora MJ, Morales-Vásquez F, Pérez-Montiel D, and Mendez C
- Subjects
- Adult, Carcinoma, Endometrioid metabolism, Carcinoma, Ovarian Epithelial metabolism, Carcinoma, Ovarian Epithelial pathology, Cell Proliferation drug effects, Female, Humans, Middle Aged, Ovarian Neoplasms metabolism, Prospective Studies, Receptors, Progesterone metabolism, Receptors, Steroid metabolism, Tumor Cells, Cultured drug effects, Antineoplastic Agents, Hormonal pharmacology, Carcinoma, Endometrioid pathology, Cell Survival drug effects, Ovarian Neoplasms pathology, Progesterone pharmacology
- Abstract
Background: Ovarian cancer is the most lethal of all gynecologic malignancies. The relationship between sexual steroids receptors and ovarian cancer progression has been largely evaluated. The presence of progesterone receptors has been associated with an increase of a disease-free period and overall survival in patients with ovarian carcinoma. In the present study, primary cultures of ovarian carcinoma obtained from 35 patients diagnosed with epithelial ovarian cancer were evaluated for cell survival after treatment with 10
- 8 M of 17β-estradiol, progesterone, testosterone and dihydrotestosterone., Results: The results were analyzed considering histological subtypes: low grade serous, high grade serous, endometrioid and mucinous carcinoma; clear cell carcinoma was not included due to failure in obtaining successful cultures of this subtype. A significant reduction of cell survival was observed after progesterone treatment in endometrioid ovarian carcinoma. Changes were not observed in low grade serous, high grade serous and mucinous carcinoma. The effect of progesterone was related to the presence of progesterone receptor (PR), a 43% reduction in the cell number was observed in PR (+) endometrioid ovarian carcinoma., Conclusions: This study supports the importance of progesterone and the presence of progesterone receptor in the reduction of ovarian cancer progression in the endometrioid ovarian carcinoma.- Published
- 2019
- Full Text
- View/download PDF